Hangzhou Biotest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	1,591	1,907	1,940	1,368
Short-Term Investments	-	-	10	-	-
Trading Asset Securities	-	60.26	-	100.06	360.84
Cash & Short-Term Investments	1,524	1,651	1,917	2,040	1,729
Cash Growth	-7.72%	-13.88%	-6.01%	18.02%	561.86%
Accounts Receivable	-	97.46	61.89	38.82	146.91
Other Receivables	-	4.27	2.8	1.6	8.32
Receivables	-	101.73	64.68	40.42	155.23
Inventory	-	73.4	99.32	135.2	141.7
Other Current Assets	-	51.57	5.37	19.6	7.2
Total Current Assets	-	1,878	2,087	2,235	2,033
Property, Plant & Equipment	-	408.81	261.58	244.68	231.02
Long-Term Investments	-	19.3	2.84	40	40
Other Intangible Assets	-	275.16	208.71	213.71	20.35
Long-Term Deferred Tax Assets	-	11.8	14.44	13.16	3.01
Long-Term Deferred Charges	-	-	0.11	0.21	0.29
Other Long-Term Assets	-	9.15	5.08	4.54	104.13
Total Assets	-	2,602	2,580	2,752	2,432
Accounts Payable	-	56.45	58.35	88.72	224.32
Accrued Expenses	-	19.08	20.02	25.94	26.32
Short-Term Debt	-	0.44	0.59	0.35	5.64
Current Portion of Leases	-	-	2.45	5.1	2.28
Current Income Taxes Payable	-	0.02	-	-	39
Current Unearned Revenue	-	7.39	47.16	44.68	18.56
Other Current Liabilities	-	95.23	20.85	6.28	1.44
Total Current Liabilities	-	178.62	149.43	171.08	317.56
Long-Term Leases	-	-	-	2.19	4.55
Long-Term Unearned Revenue	-	11.17	8.69	6.43	1.25
Long-Term Deferred Tax Liabilities	-	-	0.71	1.16	-
Other Long-Term Liabilities	-	-	-	8.43	-
Total Liabilities	-	189.79	158.82	189.29	323.36
Common Stock	-	106.67	106.67	106.67	106.67
Additional Paid-In Capital	-	790.45	813.33	814.94	814.94
Retained Earnings	-	1,543	1,510	1,638	1,185
Treasury Stock	-	-31.61	-14.76	-	-
Comprehensive Income & Other	-	0.94	-0.36	1.21	0.7
Total Common Equity	2,339	2,409	2,415	2,561	2,107
Minority Interest	-	2.87	5.51	1.04	1.05
Shareholders' Equity	2,340	2,412	2,421	2,562	2,108
Total Liabilities & Equity	-	2,602	2,580	2,752	2,432
Total Debt	0.19	0.44	3.04	7.64	12.47
Net Cash (Debt)	1,523	1,651	1,914	2,032	1,716
Net Cash Growth	-7.71%	-13.77%	-5.81%	18.43%	586.22%
Net Cash Per Share	10.42	11.20	12.83	13.60	14.15
Filing Date Shares Outstanding	107.88	148.78	146.38	149.33	149.33
Total Common Shares Outstanding	107.88	148.78	148.7	149.33	149.33
Working Capital	-	1,699	1,937	2,064	1,715
Book Value Per Share	19.06	16.20	16.24	17.15	14.11
Tangible Book Value	2,068	2,134	2,207	2,348	2,087
Tangible Book Value Per Share	16.85	14.35	14.84	15.72	13.97
Buildings	-	306.67	193.65	194.71	189.13
Machinery	-	96.17	90.92	81.61	66.19
Construction In Progress	-	87.23	39.65	9.85	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.